Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated liposomal doxorubicin versus capecitabine as first-line chemotherapy in older patients with metastatic breast cancer
ISRCTN11114726Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Feb 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Pegylated liposomal doxorubicin with Capecitabine (2 arms). Primary endpoint: Progression-free survival / time to progression. Started Feb 2007; status: completed.
02
Drugs
doxorubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN11114726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11114726.